Insider · CIK 0002011534
Peter Cicala
director
Files at ERNA (Ernexa Therapeutics Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 31, 2026 | ERNA Ernexa Therapeutics Inc. | AGrant or award Stock Option (Right to buy)derivative | +5,943 | $0.00 | $0 | 5,943 | 41 d ago |
| Aug 31, 2026 | ERNA Ernexa Therapeutics Inc. | AGrant or award Stock Option (Right to buy)derivative | +5,083 | $0.00 | $0 | 5,083 | 41 d ago |
| Feb 7, 2025 | ERNA Ernexa Therapeutics Inc. | AGrant or award Stock Option (Right to buy)derivative | +51,485 | $0.00 | $0 | 51,485 | Feb 10, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.